Health Care [ 12/12 ] | Pharmaceuticals [ 58/73 ]
NASDAQ | Common Stock
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins.
Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate.
Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells.
The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers.
Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 15, 25 | -0.19 Decreased by N/A% | -1.00 Increased by +81.00% |
| Dec 6, 24 | -0.24 Decreased by N/A% | - |
| Sep 30, 24 | -0.80 Decreased by -903.13% | - |
| May 15, 24 | -0.83 Decreased by -934.38% | - |
| Oct 12, 23 | 0.00 Increased by +100.00% | -0.60 Increased by +100.00% |
| Sep 29, 23 | 0.00 Increased by +100.00% | -1.20 Increased by +100.00% |
| May 1, 23 | -0.08 Increased by +34.21% | -0.07 Decreased by -14.29% |
| Mar 30, 23 | -0.08 Decreased by -156.41% | -0.07 Decreased by -14.29% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -3.71 M Increased by +33.44% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -3.77 M Decreased by -7.63% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -2.90 M Increased by +17.40% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -7.56 M Decreased by -151.97% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -5.57 M Decreased by -656.04% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -3.50 M Decreased by -1.71% | Decreased by N/A% - |
| Sep 30, 23 | 0.00 Decreased by N/A% | -3.50 M Decreased by -1.71% | Decreased by N/A% - |
| Jun 30, 23 | 0.00 Decreased by N/A% | -3.00 M Increased by +45.89% | Decreased by N/A% Decreased by N/A% |